Context Therapeutics Inc.
CNTXHealthcare|Biotechnology|US
$0.19
+0.01 (+2.98%)
DCF Value
$0.67
Tangible Book / Share
$0.40
Cash / Share
$0.45
Analyst Consensus
Buy6 analysts
Strong Buy
0
Buy
6
Hold
0
Sell
0
Strong Sell
0
Consensus Target
$5.25
Implied Upside
+2613.2%
Low Target
$4.50
High Target
$6.00
Price Target Trend
Last Month
—
0 targets
Last Quarter
—
0 targets
Last Year
—
0 targets
All Time
$5.17
3 targets · +2572% vs price
Rating Trend
Dec 25
9 buy · 0 hold · 0 sell
Jan 26
9 buy · 0 hold · 0 sell
Feb 26
10 buy · 0 hold · 0 sell
Mar 26
10 buy · 0 hold · 0 sell
Apr 26
10 buy · 0 hold · 0 sell
May 26
10 buy · 0 hold · 0 sell
Jun 26
10 buy · 0 hold · 0 sell
Jul 26
10 buy · 0 hold · 0 sell
Aug 26
10 buy · 1 hold · 0 sell
Sep 26
9 buy · 1 hold · 0 sell
Oct 26
9 buy · 1 hold · 0 sell
Nov 26
9 buy · 1 hold · 0 sell
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 8, 2024 | H.C. Wainwright | Emily Bodnar | $6.00(+156%) | $2.34 | StreetInsider |
| May 16, 2024 | Piper Sandler | Joseph Catanzaro | $4.50(+166%) | $1.69 | StreetInsider |
| May 9, 2024 | H.C. Wainwright | Emily Bodnar | $5.00(+176%) | $1.81 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | maintain | Buy | Jun 16, 2026 |
| D. Boral Capital | maintain | Buy | Mar 24, 2026 |
| Guggenheim | maintain | Buy | Mar 24, 2026 |
| Piper Sandler | maintain | Overweight | Mar 24, 2026 |
| D. Boral Capital | maintain | Buy | Nov 6, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2025 |
| D. Boral Capital | maintain | Buy | Oct 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2025 |
| D. Boral Capital | maintain | Buy | Aug 7, 2025 |
| Piper Sandler | maintain | Overweight | Jun 26, 2025 |
| D. Boral Capital | maintain | Buy | May 8, 2025 |
| D. Boral Capital | maintain | Buy | Apr 29, 2025 |
| D. Boral Capital | maintain | Buy | Apr 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2025 |
| D. Boral Capital | maintain | Buy | Mar 21, 2025 |
| D. Boral Capital | maintain | Buy | Jan 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 10, 2024 |
| Maxim Group | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2024 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Nov 1, 2023 |
| HC Wainwright & Co. | maintain | Neutral | Jun 6, 2023 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Mar 23, 2023 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.09| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 5, 2026 | $-0.15 | $-0.09 | — | — |
| May 6, 2026 | $-0.09 | $-0.12 | — | — |
| Mar 19, 2026 | $-0.14 | $-0.11 | — | -$1.5M |
| Nov 5, 2025 | $-0.10 | $-0.09 | — | — |
| Aug 6, 2025 | $-0.09 | $-0.06 | — | — |
| May 7, 2025 | $-0.05 | $-0.05 | — | — |
| Mar 20, 2025 | $-0.04 | $-0.05 | — | — |
| Nov 6, 2024 | $-0.22 | $-0.11 | — | — |
News
New Strong Sell Stocks for October 15th
CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
Oct 15, 2026zacks.com
New Strong Sell Stocks for October 13th
ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.
Oct 13, 2026zacks.com
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the P…
Sep 9, 2026globenewswire.com